Literature DB >> 34515817

Bisphosphonate holidays: using cost-effectiveness analysis for the "yes, but" questions.

C S Colón-Emeric1, R H Lee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34515817     DOI： 10.1007/s00198-021-06064-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  7 in total

1.  Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.

Authors:  Annette L Adams; John L Adams; Marsha A Raebel; Beth T Tang; Jennifer L Kuntz; Vinutha Vijayadeva; Elizabeth A McGlynn; Wendolyn S Gozansky
Journal:  J Bone Miner Res       Date:  2018-05-24       Impact factor: 6.741

2.  Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.

Authors:  Howard A Fink; Roderick MacDonald; Mary L Forte; Christina E Rosebush; Kristine E Ensrud; John T Schousboe; Victoria A Nelson; Kristen Ullman; Mary Butler; Carin M Olson; Brent C Taylor; Michelle Brasure; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2019-04-23       Impact factor: 25.391

3.  Decision Analysis and Cost-effectiveness Analysis.

Authors:  Hilary F Ryder; Christine McDonough; Anna N A Tosteson; Jon D Lurie
Journal:  Semin Spine Surg       Date:  2009-12

4.  Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.

Authors:  Giovanni Adami; Ayesha Jaleel; Jeffrey R Curtis; Elizabeth Delzell; Rui Chen; Huifeng Yun; Shanette Daigle; Tarun Arora; Maria I Danila; Nicole C Wright; Suzanne M Cadarette; Amy Mudano; Jeffrey Foster; Kenneth G Saag
Journal:  J Bone Miner Res       Date:  2019-12-10       Impact factor: 6.741

5.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

6.  The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Jane A Cauley; Felicia Cosman; Ping Chung Leung; Peter Lakatos; Kurt Lippuner; Steven R Cummings; Trisha F Hue; Amitava Mukhopadhyay; Monique Tan; R Paul Aftring; Richard Eastell
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

7.  Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.

Authors:  Akeem A Yusuf; Steven R Cummings; Nelson B Watts; Maurille Tepie Feudjo; J Michael Sprafka; Jincheng Zhou; Haifeng Guo; Akhila Balasubramanian; Cyrus Cooper
Journal:  Arch Osteoporos       Date:  2018-03-21       Impact factor: 2.617
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.